These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26319560)

  • 1. Activation of Mitochondrial Complex II-Dependent Respiration Is Beneficial for α-Synucleinopathies.
    Fröhlich C; Zschiebsch K; Gröger V; Paarmann K; Steffen J; Thurm C; Schropp EM; Brüning T; Gellerich F; Radloff M; Schwabe R; Lachmann I; Krohn M; Ibrahim S; Pahnke J
    Mol Neurobiol; 2016 Sep; 53(7):4728-44. PubMed ID: 26319560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration.
    Wang X; Becker K; Levine N; Zhang M; Lieberman AP; Moore DJ; Ma J
    Acta Neuropathol Commun; 2019 Mar; 7(1):41. PubMed ID: 30871620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pα-syn* mitotoxicity is linked to MAPK activation and involves tau phosphorylation and aggregation at the mitochondria.
    Grassi D; Diaz-Perez N; Volpicelli-Daley LA; Lasmézas CI
    Neurobiol Dis; 2019 Apr; 124():248-262. PubMed ID: 30472299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms and models of alpha-synuclein-related neurodegeneration.
    Springer W; Kahle PJ
    Curr Neurol Neurosci Rep; 2006 Sep; 6(5):432-6. PubMed ID: 16928354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
    Gallardo G; Schlüter OM; Südhof TC
    Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional protein kinase arrays reveal inhibition of p-21-activated kinase 4 by alpha-synuclein oligomers.
    Danzer KM; Schnack C; Sutcliffe A; Hengerer B; Gillardon F
    J Neurochem; 2007 Dec; 103(6):2401-7. PubMed ID: 17883396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.
    Tsika E; Moysidou M; Guo J; Cushman M; Gannon P; Sandaltzopoulos R; Giasson BI; Krainc D; Ischiropoulos H; Mazzulli JR
    J Neurosci; 2010 Mar; 30(9):3409-18. PubMed ID: 20203200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies.
    Prots I; Grosch J; Brazdis RM; Simmnacher K; Veber V; Havlicek S; Hannappel C; Krach F; Krumbiegel M; Schütz O; Reis A; Wrasidlo W; Galasko DR; Groemer TW; Masliah E; Schlötzer-Schrehardt U; Xiang W; Winkler J; Winner B
    Proc Natl Acad Sci U S A; 2018 Jul; 115(30):7813-7818. PubMed ID: 29991596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of α-synuclein in damaged mitochondria with PLA2G6 dysfunction.
    Sumi-Akamaru H; Beck G; Shinzawa K; Kato S; Riku Y; Yoshida M; Fujimura H; Tsujimoto Y; Sakoda S; Mochizuki H
    Acta Neuropathol Commun; 2016 Mar; 4():27. PubMed ID: 27030050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
    Hashimoto M; Rockenstein E; Crews L; Masliah E
    Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired Fast Network Oscillations and Mitochondrial Dysfunction in a Mouse Model of Alpha-synucleinopathy (A30P).
    Robson E; Tweedy C; Manzanza N; Taylor JP; Atkinson P; Randall F; Reeve A; Clowry GJ; LeBeau FEN
    Neuroscience; 2018 May; 377():161-173. PubMed ID: 29524634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein.
    Marxreiter F; Nuber S; Kandasamy M; Klucken J; Aigner R; Burgmayer R; Couillard-Despres S; Riess O; Winkler J; Winner B
    Eur J Neurosci; 2009 Mar; 29(5):879-90. PubMed ID: 19291219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.
    Villar-Piqué A; Lopes da Fonseca T; Outeiro TF
    J Neurochem; 2016 Oct; 139 Suppl 1():240-255. PubMed ID: 26190401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha-Synucleinopathy models and human neuropathology: similarities and differences.
    Kahle PJ
    Acta Neuropathol; 2008 Jan; 115(1):87-95. PubMed ID: 17932682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease.
    Melo TQ; van Zomeren KC; Ferrari MF; Boddeke HW; Copray JC
    Exp Brain Res; 2017 Mar; 235(3):731-742. PubMed ID: 27866262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
    Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
    BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice.
    Casadei N; Pöhler AM; Tomás-Zapico C; Torres-Peraza J; Schwedhelm I; Witz A; Zamolo I; De Heer R; Spruijt B; Noldus LP; Klucken J; Lucas JJ; Kahle PJ; Krüger R; Riess O; Nuber S
    Hum Mol Genet; 2014 Feb; 23(3):767-81. PubMed ID: 24064336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
    Windisch M; Wolf HJ; Hutter-Paier B; Wronski R
    Curr Alzheimer Res; 2007 Dec; 4(5):556-61. PubMed ID: 18220522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation.
    Fagerqvist T; Lindström V; Nordström E; Lord A; Tucker SM; Su X; Sahlin C; Kasrayan A; Andersson J; Welander H; Näsström T; Holmquist M; Schell H; Kahle PJ; Kalimo H; Möller C; Gellerfors P; Lannfelt L; Bergström J; Ingelsson M
    J Neurochem; 2013 Jul; 126(1):131-44. PubMed ID: 23363402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein.
    Ciron C; Zheng L; Bobela W; Knott GW; Leone TC; Kelly DP; Schneider BL
    Acta Neuropathol Commun; 2015 Apr; 3():16. PubMed ID: 25853296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.